Medscape | Burkitt's Yields to Longer-Duration, Lower-Dose Chemo Medscape For 19 adults with sporadic Burkitt's lymphoma, a dose-adjusted version of the EPOCH-R (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab) regimen was associated with 95% progression-free survival and 100% overall ... Low-intensity therapy very effective in Burkitt lymphoma |
